Efficacy and safety of suprachoroidal triamcinolone acetonide in cases of resistant diabetic macular edema
Authors:
Open Access
- 13 December 2019
- journal article
- research article
- Published by Pakistan Journal of Medical Sciences in Pakistan Journal of Medical Sciences
- Vol. 36 (2) , 42-47
Abstract
Objective: To evaluate the safety and efficacy of Suprachoroidal Triamcinolone Acetonide (SCTA) injection in patients with treatment resistant Diabetic Macular Edema (DME). Methods: This was a prospective non randomized interventional study conducted in the vitreoretinal department of Al Ehsan Welfare Eye Hospital, Lahore, Pakistan from March 2018 to September 2018. A total of 24 eyes of 24 patients were included. Baseline Best Corrected Visual Acuity (BCVA), Intra Ocular Pressure (IOP) and Central Subfield Thickness (CST) was recorded. After SCTA, patient was followed up at one and three months and same clinical parameters were recorded again and results analyzed. Results: Out of 24 patients, 11(45.83%) were males and 13(54.16%) were females. Mean pre injection CST was 636.5 ± 200.11 um. Mean pre injection BCVA was 0.8 ± 0.24 on ETDRS chart. Mean post injection CST at one and three months was 304.54 ± 67.43 and 302.66 ± 66.93 um. Mean post injection BCVA at one and three months was 0.47 ± 0.3 and 0.45 ± 0.27 on ETDRS chart. The results were statistically significant for pre and post injection CST at both one and three months (p-value < 0.00001). Pre and post injection BCVA was also statistically significant (p-value < 0.05). Conclusion: Preliminary evidence suggests that SCTA is well tolerated and may help in improving functional and structural outcomes of treatment resistant DME. doi: https://doi.org/10.12669/pjms.36.2.1194 How to cite this:Tayyab H, Ahmed CN, Sadiq MAA. Efficacy and safety of suprachoroidal triamcinolone acetonide in cases of resistant diabetic macular edema. Pak J Med Sci. 2020;36(2):42-47. doi: https://doi.org/10.12669/pjms.36.2.1194 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Keywords
This publication has 19 references indexed in Scilit:
- Suprachoroidal Triamcinolone Acetonide for Diabetic Macular EdemaOphthalmology Retina, 2018
- A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edemaBMC Ophthalmology, 2018
- Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite StudyOphthalmology Retina, 2018
- Choroidal Changes After Suprachoroidal Injection of Triamcinolone Acetonide in Eyes With Macular Edema Secondary to Retinal Vein OcclusionAmerican Journal of Ophthalmology, 2018
- Dexamethasone implant (0.7 mg) in Indian patients with macular edema: Real-life scenarioTaiwan Journal of Ophthalmology, 2018
- Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)Ophthalmologica, 2017
- Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1)Clinical Ophthalmology, 2017
- Suprachoroidal Corticosteroid Administration: A Novel Route for Local Treatment of Noninfectious UveitisTranslational Vision Science & Technology, 2016
- Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial ResultsOphthalmology, 2015
- Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2010